NCT01950481View on ClinicalTrials.gov

Effect of Hepatic Impairment on LDK378 Pharmacokinetics

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Normal Hepatic FunctionImpaired Hepatic Function
Interventions
DRUG

LDK378

Oral LDK378 750 mg once

Trial Locations (5)

32086

Orlando Clinical Research Center, Orlando

32720

Avail. Clinical Research, LLC, DeLand

33126

Clinical Research of Miami, INC CLDK378A2110, Miami

55404

DaVita Clinical Research, Minneapolis

80228

DaVita Clinical Research-Denver, Lakewood

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY